European Journal of Clinical Pharmacology

, Volume 39, Issue 1, pp 29–31 | Cite as

Does N-acetylcysteine increase the excretion of trace metals (calcium, magnesium, iron, zinc and copper) when given orally?

  • E. Hjortsrø
  • J. S. Fomsgaard
  • N. Fogh-Andersen
Article

Summary

N-Acetylcysteine (NAC) is known to decrease the exacerbation rate in patients with chronic bronchitis. It has also been shown that NAC has both an oxygen-radical scavenger and a heavy-metal chelating effect in high intravenous doses. In a study lasting 5 weeks, 10 healthy volunteers were treated with NAC 200 mg t. d. s. for two weeks. The concentrations of trace metals (Ca, Mg, Fe, Zn & Cu) in plasma were measured weekly and daily in a morning spot urine during the investigation.

No significant change in plasma concentration or excretion was found during the two weeks of treatment, implying that additional administration of trace metals is unnecessary for patients treated perorally with a therapeutic dose of NAC.

Key words

Acetylcysteine Metal excretion Trace metals NAC 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sheffner AL (1963) The reduction in vitro in viscosity of muco- protein solutions by a new mucolytic agent, N-Acetylcysteine. Ann NY Acad Sci 106:298–310PubMedCrossRefGoogle Scholar
  2. 2.
    Hurst GA, Shaw PB, LeMaistre CA (1967) Laboratory and clini- cal evaluation of the mucolytic properties of acetylcysteine. Am Rev Respir Dis 96: 962–970PubMedGoogle Scholar
  3. 3.
    Kory RC, Hirsch RS, Giraldo J (1968) Nebulization of N-Ace- tylcysteine combined with a bronchodilator in patients with chronic bronchitis. Dis Chest 54:18–23Google Scholar
  4. 4.
    Cotgreave IA, Eklund A, Larsson K, Moldéus PW (1987) No penetration of orally administered N-acetylcysteine into bron- choalveolar lavage fluid. Eur J Respir Dis 70:73–77PubMedGoogle Scholar
  5. 5.
    Jeffery P (1986) Anti-inflammatory drugs and experimental bronchitis. Eur J Respir Dis 69 [Supp1 146]: 245–257Google Scholar
  6. 6.
    Grassi C, Morandini GC (1976) A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bron- chitis. Eur J Clin Pharmacol 9:393–396CrossRefGoogle Scholar
  7. 7.
    Boman G, Bficker U, Larsson S, Melander B, Wåhlander L (1983) Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis 64:405–415PubMedGoogle Scholar
  8. 8.
    Moldéus P, Cotgrave IA, Berggren M (1986) Lung protection by a thiol-containing antioxidant: N-Acetylcysteine. Respiration 50: [Suppl 1] 31–42PubMedGoogle Scholar
  9. 9.
    Wagner PD, Mathieu-Costello O, Bebout DE, Gray AT, Natter- son PD, Glennow C (1989) Protection against pulmonary O2tox- icity by N-Acetylcysteine. Eur Respir J 2:116–126PubMedGoogle Scholar
  10. 10.
    Lorber A, Baumgartner WA, Bovy RA, Chang CC, Hollcraft R (1973) Ctincal application for heavy metal-complexing potential of N-Acetylcysteine. J Clin Pharmaco1 13:332–336Google Scholar
  11. 11.
    Gofrey NF, Peter A, Simon TM, Lorber A (1982) IV N-Ace- tylcysteine treatment of hematologic reactions to chrysotherapy. JRheumatol 9:519–526Google Scholar
  12. 12.
    Hjortsr E, Qvist J, Bud MIet al. (1988) ARDS after accidental inhalation of zinc chloride smoke. Int Care Med 27:522–525Google Scholar
  13. 13.
    Weidner MG, Clowes GHA (1960) The role of the kidney in hy- pocalcemia induced by citrate infusion. Surg Forum 10:444–449PubMedGoogle Scholar
  14. 14.
    Walser M (1961) Ion association. VII. Dependence of calciuresis on natriuresis during sulfate infusion. Am J Physio1 201:769–773Google Scholar
  15. 15.
    Olsson B, Johansson M, Gabrielsson J, Bolme P (1988) Pharma- cokinetics and bioavailability of reduced and oxidized N-Ace- tylcysteine. Eur J Clin Pharmaco1 34:77–82CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • E. Hjortsrø
    • 1
  • J. S. Fomsgaard
    • 1
  • N. Fogh-Andersen
    • 2
  1. 1.Departments of AnaesthesiologyUniversity of CopenhagenDenmark
  2. 2.Clinical Chemistry, Herlev HospitalUniversity of CopenhagenDenmark

Personalised recommendations